Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 84Neoplasm Metastasis 8Neoplasms 6Sarcoma 4Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Untreated Operable Early Breast Cancer 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Somatostatinoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × palbociclib × Clear all
NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Completed
53 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡